Torrent Pharma's Stock Hits 52-Week High and Receives 'Buy' Call from MarketsMOJO
Torrent Pharmaceuticals Ltd. (Torrent Pharma) has achieved a new milestone as its stock price hit a 52-week high on October 9, 2024. According to MarketsMojo, the company's stock has been given a 'Buy' call, indicating its potential for growth. With a 5.35% increase in returns and outperforming its sector, Torrent Pharma is showing strong performance in the market.
Torrent Pharmaceuticals Ltd. (Torrent Pharma) has reached a new milestone as its stock price hit a 52-week high on October 9, 2024. The company, which operates in the pharmaceuticals and drugs industry, has been gaining momentum in the market with its recent performance.
According to MarketsMOJO, a leading stock market analysis and research platform, Torrent Pharma's stock has been given a 'Buy' call. This is a positive sign for investors, indicating that the company's stock is expected to perform well in the market.
On October 9, the stock reached a new high of Rs. 3582, outperforming the sector by 1.01%. This is a significant achievement for the company, as it shows that it is performing better than its competitors in the industry.
In the past two days, Torrent Pharma's stock has been on a consecutive rise, with a 5.35% increase in returns. The stock has also shown high volatility, with an intraday volatility of 126.23%. This indicates that the stock is actively traded and has the potential for further growth.
Moreover, Torrent Pharma's stock is currently trading higher than its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages. This is a strong indication of the company's positive performance in the market.
In comparison to the Sensex, a benchmark index for the Indian stock market, Torrent Pharma has shown an impressive 1-year performance of 88.11%, while the Sensex has only grown by 24.83%. This further highlights the company's strong performance and potential for growth.
Overall, Torrent Pharmaceuticals Ltd. has shown promising growth in the market, with its stock reaching a new high and receiving a 'Buy' call from MarketsMOJO. With its strong performance and positive outlook, the company is definitely one to watch in the pharmaceuticals and drugs industry.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
